ATE307610T1 - Verfahren zum stabilisieren von arylcarbonsäuren, dafür verwendbarer stabilisator und eine stabilisierte carbonsäure enthaltende wässrige lösung - Google Patents

Verfahren zum stabilisieren von arylcarbonsäuren, dafür verwendbarer stabilisator und eine stabilisierte carbonsäure enthaltende wässrige lösung

Info

Publication number
ATE307610T1
ATE307610T1 AT03025332T AT03025332T ATE307610T1 AT E307610 T1 ATE307610 T1 AT E307610T1 AT 03025332 T AT03025332 T AT 03025332T AT 03025332 T AT03025332 T AT 03025332T AT E307610 T1 ATE307610 T1 AT E307610T1
Authority
AT
Austria
Prior art keywords
aqueous solution
stabilizing
solution containing
carboxylic acid
arylcarboxylic acids
Prior art date
Application number
AT03025332T
Other languages
English (en)
Inventor
Sawa Shirou
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Application granted granted Critical
Publication of ATE307610T1 publication Critical patent/ATE307610T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03025332T 1997-02-04 1998-02-03 Verfahren zum stabilisieren von arylcarbonsäuren, dafür verwendbarer stabilisator und eine stabilisierte carbonsäure enthaltende wässrige lösung ATE307610T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2180597 1997-02-04

Publications (1)

Publication Number Publication Date
ATE307610T1 true ATE307610T1 (de) 2005-11-15

Family

ID=12065276

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03025332T ATE307610T1 (de) 1997-02-04 1998-02-03 Verfahren zum stabilisieren von arylcarbonsäuren, dafür verwendbarer stabilisator und eine stabilisierte carbonsäure enthaltende wässrige lösung
AT98101804T ATE253891T1 (de) 1997-02-04 1998-02-03 Verfahren zum stabilisieren von arylcarbonsäuren, dafür verwendbaren stabilisator und eine stabilisierte carbonsäure enthaltende wässrige lösung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98101804T ATE253891T1 (de) 1997-02-04 1998-02-03 Verfahren zum stabilisieren von arylcarbonsäuren, dafür verwendbaren stabilisator und eine stabilisierte carbonsäure enthaltende wässrige lösung

Country Status (7)

Country Link
US (3) US6274592B1 (de)
EP (2) EP0856310B1 (de)
KR (1) KR100506484B1 (de)
AT (2) ATE307610T1 (de)
CA (1) CA2228536A1 (de)
DE (2) DE69832115T2 (de)
ES (1) ES2250814T3 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1264837C (zh) 1997-09-15 2006-07-19 普罗克特和甘保尔公司 喹诺酮抗微生物剂、其组合物和应用
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
AU2002354575A1 (en) 2001-07-12 2003-01-29 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
BR0212829A (pt) * 2001-09-26 2004-08-03 Bayer Pharmaceuticals Corp Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
WO2004064828A1 (ja) * 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤
BRPI0709209A2 (pt) 2006-03-28 2011-06-28 Procter & Gamble processo de redução de hidreto para preparo de intermediários de quinolona
ES2366150T3 (es) 2006-03-28 2011-10-17 Warner Chilcott Company, Llc Malatos de polimorfos de ácido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolinocarboxílico.
CA2647454A1 (en) 2006-03-28 2007-10-04 The Procter & Gamble Company A coupling process for preparing quinolone intermediates
US9107888B2 (en) 2011-01-18 2015-08-18 Senju Pharmaceutical Co., Ltd. Aqueous liquid bromfenac composition having preservative efficacy
JP6073231B2 (ja) * 2011-08-31 2017-02-01 興和株式会社 安定な医薬組成物
SMT202500447T1 (it) 2021-11-02 2026-01-12 Flare Therapeutics Inc Agonisti inversi di pparg e loro usi
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB873526A (en) 1957-08-14 1961-07-26 Upjohn Co Fluid compositions comprising (acetyl-salicylic acid)-anhydride
US4339428A (en) 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
US4559343A (en) 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
AU573321B2 (en) 1984-03-14 1988-06-02 Jerome Corbiere Process for solubilizing active principles and pharmaceuticalcompositions thus obtained
IL80459A (en) 1986-10-30 1991-04-15 Abic Ltd Water-soluble adduct of norfloxacin and nicotinic acid
IT1226940B (it) 1988-09-16 1991-02-22 Recordati Chem Pharm Sistema terapeutico a rilascio controllato per formulazioni farmaceutiche liquide
CA1336687C (en) 1989-08-23 1995-08-15 Thomas M. Tencza Process for preparing tablets containing ibuprofen, apap and caffeine, the products of this process and the use of such products
US5296228A (en) 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
ES2065846B1 (es) * 1993-04-20 1995-10-01 Cusi Lab Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
TW256831B (de) 1993-04-22 1995-09-11 Senju Pharma Co
AU676315B2 (en) 1993-06-30 1997-03-06 Takeda Chemical Industries Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
JPH0797325A (ja) 1993-06-30 1995-04-11 Takeda Chem Ind Ltd 安定な固形製剤およびその製造法
HUT72408A (en) 1993-09-10 1996-04-29 Egyt Gyogyszervegyeszeti Gyar Process for producing tablets containing acetyl-salicylic acid
US5641512A (en) 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
JP3170619B2 (ja) * 1995-04-20 2001-05-28 参天製薬株式会社 有機アミンを配合したプラノプロフェン点眼液
JPH08333265A (ja) 1995-06-07 1996-12-17 Taisho Pharmaceut Co Ltd イブプロフェン懸濁液剤
JPH08333246A (ja) 1995-06-07 1996-12-17 Taisho Pharmaceut Co Ltd イブプロフェン懸濁液剤
JP3382076B2 (ja) 1995-12-12 2003-03-04 佐藤製薬株式会社 イブプロフェンを溶解してなるかぜ薬軟カプセル及びその製造方法
GB9613457D0 (en) 1996-06-27 1996-08-28 Procter & Gamble Pharmaceutical compositions
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid

Also Published As

Publication number Publication date
US20010056098A1 (en) 2001-12-27
EP0856310A3 (de) 2000-01-19
EP1389469B1 (de) 2005-10-26
US6274592B1 (en) 2001-08-14
EP0856310B1 (de) 2003-11-12
DE69819569D1 (de) 2003-12-18
ES2250814T3 (es) 2006-04-16
DE69832115T2 (de) 2006-07-13
US7320985B2 (en) 2008-01-22
ATE253891T1 (de) 2003-11-15
EP0856310A2 (de) 1998-08-05
KR19980071023A (ko) 1998-10-26
KR100506484B1 (ko) 2005-11-16
DE69832115D1 (de) 2005-12-01
CA2228536A1 (en) 1998-08-04
US20050075350A1 (en) 2005-04-07
EP1389469A1 (de) 2004-02-18

Similar Documents

Publication Publication Date Title
ATE253891T1 (de) Verfahren zum stabilisieren von arylcarbonsäuren, dafür verwendbaren stabilisator und eine stabilisierte carbonsäure enthaltende wässrige lösung
ES2173499T3 (es) Sales de adicion de acidos de compuesto de piperidina opticamente activo y procedimiento para su preparacion.
DE69932313D1 (de) Wässerige flüssige zubereitungen
ATE13422T1 (de) Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems.
ATE511508T1 (de) Verfahren zur kristallisation von (r)- oder (s)- lansoprazol
ES2132284T3 (es) Derivados de carbamato de 2-(piperidin-4-il, piridin-4-il y tetrahidropiridin-4-il)-benzofurano-7, su preparacion y su uso como inhibidores de acetilcolinesterasa.
DK0882725T3 (da) Quinoloncarboxylsyrederivater eller deres salte
NO307180B1 (no) En-kolbe-metode for fremstilling av 3- kinolonkarboksylsyrederivater
NO20005660L (no) Nye mellomprodukter og fremgangsmåter for fremstilling av optisk aktive oktansyrederivater
ES514463A0 (es) "procedimiento de escision enzimatica de derivados de insulina".
DK0415102T3 (da) 1,3-Dihydro-1-(pyridinylamino)-2H-indol-2-oner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
ATE239505T1 (de) Verfahren zum löslichmachen von pyridoncarbonsäuren mit hilfe von arylcarbonsäuren als lösungsvermittler
TW256831B (de)
DE69321749D1 (de) Verfahren zur Herstellung von Ceftriaxon
KR960704878A (ko) 광학 활성 이미다졸리딘온 유도체 및 이의 제조방법 (Optically active imidazolidinone derivative and process for producing the same)
ATE389010T1 (de) Verfahren zur herstellung von optisch aktiven pyridinethanol-derivaten
DE3789409D1 (de) Verfahren zur Herstellung von Chinolin-2,3-Carbonsäure.
DE69928610D1 (de) Verfahren zur Herstellung von 2-Carbamoyl-Pyridinen
DE60019723D1 (de) Eine methode zur herstellung von verbindungen der formel 1 und derivaten
ATE215528T1 (de) Verfahren zur herstellung von alpha- aminosäureamide, alpha-aminosäuren und ihre derivaten
BR9405262A (pt) Processo para a preparação de um ácido piridina-2,3-dicarboxílico
DE3262353D1 (en) N,n-disubstituted alkenamides and phenylalkenamides, processes for their production and their use as pharmaceuticals
PT83715B (pt) Processo para a preparacao de novos derivados de piperidina
DE69816773D1 (de) Verfahren zur herstellung von 1,4-benzodioxan-derivaten
ES2195309T3 (es) Derivados de tetrahidrofurano.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties